Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CEND-1||CEND1|CEND 1||CEND-1 is a peptide that is targeted to tumors via interaction with alpha-integrins and potentially increases the delivery of other antitumor agents via interaction with neuropilin-1 (Annals of Oncology 31 (2020): S941).|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 14||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Leucovorin||Wellcovorin||Calcium folinate|Calcium citrovorum factor|folinic acid||Chemotherapy - Antimetabolite 14||Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554).|
|Oxaliplatin||Eloxatin||Diaminocyclohexane Oxalatoplatinum||Chemotherapy - Platinum 7||Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).|
|Panitumumab||Vectibix||ABX-EGF||EGFR Antibody 42||Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05121038||Phase Ib/II||CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab||CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX)||Recruiting||USA||0|